Home HOME Neoplasma 2011 Neoplasma Vol.58, No.4, p.277-282, 2011

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.58, No.4, p.277-282, 2011

Title: Clinical relevance of thiopurine S-methyltransferase gene polymorphisms
Author: B. MLADOSIEVICOVA, A. DZURENKOVA, S. SUFLIARSKA, A. CARTER

Abstract: The therapeutic response to thiopurines may result in either severe toxic or inadequate effect based on the interindividual genetic variability. Same drug doses of various anticancer drugs cause considerable interindividual differences in the therapeutic response. Genetic factors have a major impact on effectiveness of several anticancer drugs such as mercaptopurine, 5-fluorouracil, platinum agents, and cyclophosphamide. Heredity related differences in interindividual response to thiopurine therapy represent perhaps the most compelling evidence of pharmacogenomics‘ usefulness in identification of patients in risk for adverse drug reactions. A number of variations in the gene for thiopurine methyltransferase (TPMT) have been associated with the low activity of this enzyme. Patients with intermediate and low activity of TPMT have a greater incidence of thiopurine toxicity. This minireview summarizes results of studies assessing the role of genetic polymorphisms in the gene encoding TPMT and their relationship to the toxicity of thiopurines.

Keywords: toxicity, thiopurines, thiopurine methyltransferase (TPMT), polymorphism
Year: 2011, Volume: 58, Issue: 4 Page From: 277, Page To: 282
doi:10.4149/neo_2011_04_277
Price: 14.40 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.